According to Fierce Biotech, GSK or Pfizer have been named as the front runners by industry observers as most likely to acquire Onyx. Takeda was also mentioned as being in the race. Onyx makes Nexavar (kidney cancer) and has the hotly watched carfilzomib (multiple myeloma) under FDA review. Analysts project Onyx revenues more than doubling in the next 5 years.
That will help any acquirer fill in some of those nasty revenue potholes caused by drugs going over the patent cliff. Let the bidding begin and place your bets on the winner.
Posted by Bruce Lehr Dec 1st 2011.